These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32511342)

  • 1. Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Nelson RE; Singh S; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    bioRxiv; 2020 May; ():. PubMed ID: 32511342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.
    Wang L; Shi W; Chappell JD; Joyce MG; Zhang Y; Kanekiyo M; Becker MM; van Doremalen N; Fischer R; Wang N; Corbett KS; Choe M; Mason RD; Van Galen JG; Zhou T; Saunders KO; Tatti KM; Haynes LM; Kwong PD; Modjarrad K; Kong WP; McLellan JS; Denison MR; Munster VJ; Mascola JR; Graham BS
    J Virol; 2018 May; 92(10):. PubMed ID: 29514901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein.
    Bordoloi D; Xu Z; Ho M; Purwar M; Bhojnagarwala P; Cassel J; Giron LB; Walker S; Kulkarni AJ; Ruiz ET; Choi J; Zaidi FI; Wu Y; Wang S; Patel A; Ramos S; Smith T; Kulp D; Ugen KE; Srinivasan A; Abdel-Mohsen M; Humeau L; Weiner DB; Muthumani K
    ACS Pharmacol Transl Sci; 2021 Aug; 4(4):1349-1361. PubMed ID: 34396059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits.
    Ravichandran S; Coyle EM; Klenow L; Tang J; Grubbs G; Liu S; Wang T; Golding H; Khurana S
    Sci Transl Med; 2020 Jul; 12(550):. PubMed ID: 32513867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular basis for a germline-biased neutralizing antibody response to SARS-CoV-2.
    Clark SA; Clark LE; Pan J; Coscia A; McKay LGA; Shankar S; Johnson RI; Griffiths A; Abraham J
    bioRxiv; 2020 Nov; ():. PubMed ID: 33200128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-CoV-2 using a competitive phage biopanning strategy.
    Zeng X; Li L; Lin J; Li X; Liu B; Kong Y; Zeng S; Du J; Xiao H; Zhang T; Zhang S; Liu J
    Antib Ther; 2020 Apr; 3(2):95-100. PubMed ID: 33912790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies.
    Barnes CO; West AP; Huey-Tubman KE; Hoffmann MAG; Sharaf NG; Hoffman PR; Koranda N; Gristick HB; Gaebler C; Muecksch F; Cetrulo Lorenzi JC; Finkin S; Hagglof T; Hurley A; Millard KG; Weisblum Y; Schmidt F; Hatziioannou T; Bieniasz PD; Caskey M; Robbiani DF; Nussenzweig MC; Bjorkman PJ
    bioRxiv; 2020 May; ():. PubMed ID: 32577645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike.
    Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Lista MJ; Jimenez-Guardeno JM; Laing AG; Wu Y; Joseph M; Muir L; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
    bioRxiv; 2021 Feb; ():. PubMed ID: 33564766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of the spike protein RBD from SARS-CoV-2 with ACE2: Similarity with SARS-CoV, hot-spot analysis and effect of the receptor polymorphism.
    Othman H; Bouslama Z; Brandenburg JT; da Rocha J; Hamdi Y; Ghedira K; Srairi-Abid N; Hazelhurst S
    Biochem Biophys Res Commun; 2020 Jun; 527(3):702-708. PubMed ID: 32410735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses.
    Yang Y; Shi W; Abiona OM; Nazzari A; Olia AS; Ou L; Phung E; Stephens T; Tsybovsky Y; Verardi R; Wang S; Werner A; Yap C; Ambrozak D; Bylund T; Liu T; Nguyen R; Wang L; Zhang B; Zhou T; Chuang GY; Graham BS; Mascola JR; Corbett KS; Kwong PD
    Vaccines (Basel); 2021 Jan; 9(2):. PubMed ID: 33494381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural classification of neutralizing antibodies against the SARS-CoV-2 spike receptor-binding domain suggests vaccine and therapeutic strategies.
    Barnes CO; Jette CA; Abernathy ME; Dam KA; Esswein SR; Gristick HB; Malyutin AG; Sharaf NG; Huey-Tubman KE; Lee YE; Robbiani DF; Nussenzweig MC; West AP; Bjorkman PJ
    bioRxiv; 2020 Aug; ():. PubMed ID: 32869026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Human Single-Domain Antibodies against SARS-CoV-2.
    Wu Y; Li C; Xia S; Tian X; Kong Y; Wang Z; Gu C; Zhang R; Tu C; Xie Y; Yang Z; Lu L; Jiang S; Ying T
    Cell Host Microbe; 2020 Jun; 27(6):891-898.e5. PubMed ID: 32413276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin fragment F(ab')
    Pan X; Zhou P; Fan T; Wu Y; Zhang J; Shi X; Shang W; Fang L; Jiang X; Shi J; Sun Y; Zhao S; Gong R; Chen Z; Xiao G
    Antiviral Res; 2020 Oct; 182():104868. PubMed ID: 32659292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.
    Brouwer PJM; Caniels TG; van der Straten K; Snitselaar JL; Aldon Y; Bangaru S; Torres JL; Okba NMA; Claireaux M; Kerster G; Bentlage AEH; van Haaren MM; Guerra D; Burger JA; Schermer EE; Verheul KD; van der Velde N; van der Kooi A; van Schooten J; van Breemen MJ; Bijl TPL; Sliepen K; Aartse A; Derking R; Bontjer I; Kootstra NA; Wiersinga WJ; Vidarsson G; Haagmans BL; Ward AB; de Bree GJ; Sanders RW; van Gils MJ
    Science; 2020 Aug; 369(6504):643-650. PubMed ID: 32540902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana.
    Rattanapisit K; Shanmugaraj B; Manopwisedjaroen S; Purwono PB; Siriwattananon K; Khorattanakulchai N; Hanittinan O; Boonyayothin W; Thitithanyanont A; Smith DR; Phoolcharoen W
    Sci Rep; 2020 Oct; 10(1):17698. PubMed ID: 33077899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals.
    Beaudoin-Bussières G; Laumaea A; Anand SP; Prévost J; Gasser R; Goyette G; Medjahed H; Perreault J; Tremblay T; Lewin A; Gokool L; Morrisseau C; Bégin P; Tremblay C; Martel-Laferrière V; Kaufmann DE; Richard J; Bazin R; Finzi A
    mBio; 2020 Oct; 11(5):. PubMed ID: 33067385
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potently neutralizing human antibodies that block SARS-CoV-2 receptor binding and protect animals.
    Zost SJ; Gilchuk P; Case JB; Binshtein E; Chen RE; Reidy JX; Trivette A; Nargi RS; Sutton RE; Suryadevara N; Williamson LE; Chen EC; Jones T; Day S; Myers L; Hassan AO; Kafai NM; Winkler ES; Fox JM; Steinhardt JJ; Ren K; Loo YM; Kallewaard NL; Martinez DR; Schäfer A; Gralinski LE; Baric RS; Thackray LB; Diamond MS; Carnahan RH; Crowe JE
    bioRxiv; 2020 May; ():. PubMed ID: 32511409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.